1. Adoption of triplet therapy and clinical outcomes in routine practice among newly diagnosed multiple myeloma patients not receiving frontline stem cell transplant in the USA. Issue 1 (2nd January 2019) Authors: Hari, Parameswaran; Blazer, Marlo; Raju, Aditya; Farrelly, Eileen; Labotka, Richard; Skacel, Tomas; Romanus, Dorothy Journal: Expert review of hematology Issue: Volume 12:Issue 1(2019) Page Start: 71 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. (January 2019) Authors: Dimopoulos, Meletios A.; Grosicki, Sebastian; Jędrzejczak, Wiesław W.; Nahi, Hareth; Gruber, Astrid; Hansson, Markus; Gupta, Neeraj; Byrne, Catriona; Labotka, Richard; Teng, Zhaoyang; Yang, Huyuan; Grzasko, Norbert; Kumar, Shaji Journal: European journal of cancer Issue: Volume 106(2019) Page Start: 89 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Disease burden of systemic light-chain amyloidosis: a systematic literature review. (3rd June 2017) Authors: Lin, Huamao Mark; Gao, Xin; Cooke, Catherine E.; Berg, Deborah; Labotka, Richard; Faller, Douglas V.; Seal, Brian; Hari, Parameswaran Journal: Current medical research and opinion Issue: Volume 33:Number 6(2017) Page Start: 1017 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. Issue 22 (1st August 2021) Authors: Richardson, Paul G.; Kumar, Shaji K.; Masszi, Tamás; Grzasko, Norbert; Bahlis, Nizar J.; Hansson, Markus; Pour, Luděk; Sandhu, Irwindeep; Ganly, Peter; Baker, Bartrum W.; Jackson, Sharon R.; Stoppa, Anne-Marie; Gimsing, Peter; Garderet, Laurent; Touzeau, Cyrille; Buadi, Francis K.; Laubach, Jacob... Journal: Journal of clinical oncology Issue: Volume 39:Issue 22(2021) Page Start: 2430 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Impact of ixazomib‐lenalidomide‐dexamethasone therapy on overall survival in multiple myeloma patients: Analysis of the emerging‐markets subgroup of the TOURMALINE‐MM1 trial. Issue 4 (31st August 2022) Authors: Spencer, Andrew; Samoilova, Olga; Chng, Wee‐Joo; Labotka, Richard; Li, Cong; Wu, Kwang‐Wei; Saxena, Nakul; Yan, Xu; Lee, Jae Hoon; Beksac, Meral Journal: EJHaem Issue: Volume 3:Issue 4(2022) Page Start: 1241 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies. (8th May 2019) Authors: Dimopoulos, Meletios A.; Laubach, Jacob P.; Echeveste Gutierrez, Maria Asunción; Grzasko, Norbert; Hofmeister, Craig C.; San‐Miguel, Jesus F.; Kumar, Shaji; Labotka, Richard; Lu, Vickie; Berg, Deborah; Byrne, Catriona; Teng, Zhaoyang; Liu, Guohui; van de Velde, Helgi; Richardson, Paul G. Journal: European journal of haematology Issue: Volume 102:Number 6(2019) Page Start: 494 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Model‐Based Meta‐Analysis for Multiple Myeloma: A Quantitative Drug‐Independent Framework for Efficient Decisions in Oncology Drug Development. Issue 2 (23rd November 2017) Authors: Teng, Zhaoyang; Gupta, Neeraj; Hua, Zhaowei; Liu, Guohui; Samnotra, Vivek; Venkatakrishnan, Karthik; Labotka, Richard Journal: Clinical and translational science Issue: Volume 11:Issue 2(2018) Page Start: 218 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Model‐Informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor. Issue 2 (23rd March 2018) Authors: Gupta, Neeraj; Hanley, Michael J.; Diderichsen, Paul M.; Yang, Huyuan; Ke, Alice; Teng, Zhaoyang; Labotka, Richard; Berg, Deborah; Patel, Chirag; Liu, Guohui; van de Velde, Helgi; Venkatakrishnan, Karthik Journal: Clinical pharmacology & therapeutics Issue: Volume 105:Issue 2(2019) Page Start: 376 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. Issue 10168 (19th January 2019) Authors: Dimopoulos, Meletios A; Gay, Francesca; Schjesvold, Fredrik; Beksac, Meral; Hajek, Roman; Weisel, Katja Christina; Goldschmidt, Hartmut; Maisnar, Vladimir; Moreau, Philippe; Min, Chang Ki; Pluta, Agnieszka; Chng, Wee-Joo; Kaiser, Martin; Zweegman, Sonja; Mateos, Maria-Victoria; Spencer, Andrew; I... Journal: Lancet Issue: Volume 393:Issue 10168(2019) Page Start: 253 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment. (29th May 2016) Authors: Gupta, Neeraj; Hanley, Michael J.; Venkatakrishnan, Karthik; Perez, Raymond; Norris, Robin E.; Nemunaitis, John; Yang, Huyuan; Qian, Mark G.; Falchook, Gerald; Labotka, Richard; Fu, Siqing Journal: British journal of clinical pharmacology Issue: Volume 82:Number 3(2016:Sep.) Page Start: 728 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗